Molecular Cancer Therapeutics

Article	Citations
Selected Articles from This Issue	120
Abstract B048: Fibroblast Growth Factor Receptor 2 Alterations in non-Cholangiocarcinoma Gastrointestinal Tumors	79
Abstract C078: DNA Nanocarrier-mediated Co-Delivery of Cisplatin and Silibinin for enhanced treatment of Oral Squamous Cell Carcinoma	71
Abstract A043: P-gp overexpression confers resistance to treatment with the antibody-drug conjugate mirvetuximab soravtansine	64
Abstract A093: VRN110755 Shows Promise with Improved Efficacy in EGFR mutation NSCLC: Highlighting CNS activity, Potency Against Resistant EGFR Mutations, and a Favorable Safety Profile	64
Abstract B119: FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models	63
Abstract A042: Evolution of resistance in brain tumors: Effects of the blood brain barrier	61
Abstract A014: Comprehensive genomic and clinicopathologic characterization of ESR1 mutations in Chinese breast cancer patients reveals distinct molecula	60
Abstract B073: Targeted Phenotype Shifting or Killing Tumor Associated Macropages (TAMs) Leading to Effective Upregulation of the Immune System Response to Solid Tumors: A Comprehensive	58
A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma	57
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition	55
Abstract B086: Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition	54
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers	53
Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer	53
Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor	47
Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)	45
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer	45
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death	42
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer	39
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer	39
Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis	38
Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model	35
Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer	33
Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors	33
Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues	33

Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabd	31
IKS04, a CanAg-Targeting Antibody–Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models	31
In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation	30
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas	30
Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma	29
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma	29
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma	28
Selected Articles from This Issue	28
Abstract A131: Sigvotatug vedotin, an integrin-beta 6 directed antibody drug conjugate, demonstrates potent single-agent antitumor activity across NSCLC subtypes and the potential to combine with targ	27
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers	27
Abstract A141: Incidence of pulmonary and hematologic adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled t	27
Expression of Concern: SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2	27
Abstract B065: Using Mutations in a Dimerization Interface of ERBB4 and ERBB2 to Elucidate the Role of ERBB4-ERBB2 Heterodimers in wild-type BRAF Melanomas	27
Abstract A092: Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer	26
Abstract A128: Identification of peptide inhibitors of KRAS G12D and Q61H mutant protein for cancer therapy	26
Abstract C128: Disrupting the Oncobiosphere: CAF-Targeting Therapy with Penetrium™ Reverses Pseudo-Resistance in Tumors	26
Abstract A032: PTEN protein and lipid phosphatase deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer	26
Abstract B018: TAK1 blockade induces DNA damage and immunogenic cGAS–STING pathway activation in pancreatic cancer	26
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors	25
Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors	25
Mechanisms of Response and Resistance to PSMA×CD3 Bispecifics in CD34+ Humanized Mice	24
Olaparib and Radiotherapy Induce Type I Interferon– and CD8+ T Cell–Dependent Sensitization to Immunotherapy in Pancreatic Cancer	24
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings	24
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism	23
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy	23
NAD+ Metabolic Enzyme Inhibitor as Radiosensitizer for Malignant Meningioma and its Modulation of P53 Expression	23
VHH-Based CAR-T Cells Targeting DLL3 Show High Efficacy in Small Cell Lung Cancer Models	22
The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years	22
A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer	22
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations	22
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models	22
MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells	22
Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (W	22
Abstract B077: Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity	21
Acknowledgement to Reviewers	21
Abstract A003: Baseline levels of HIF2 target proteins and response to the HIF2α inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma	21
Abstract C084: The farnesyl transferase inhibitor KO-2806 constrains mTORC1 activity to enhance the antitumor efficacy of mutant-selective PI3Kα inhibitors	21
Selected Articles from This Issue	21
Abstract C129: Fostamatinib as a STAT3 inhibitor and potential therapeutic for triple negative breast cancer and high grade serous ovarian cancer	21
Abstract A089: UnAcH416 (P2), a selective PRMT1 inhibitor, disrupts tumor cell growth and stress-response pathways	21
Abstract A027: First-in-class oral macrocyclic Cyclin D1-selective inhibitors demonstrate anti-tumor activity in Cyclin D1-dependent tumors	20
Abstract A072: KRAS G12C mutation and metastatic colorectal cancer: Are we ready for neo-adjuvant? A case report.	20
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS	20
Abstract B062: Loss of Flotillin-2 increases Trastuzumab emtansine internalization and cytotoxicity in HER2 amplified cancers	19
Abstract A016: cfDNA fragmentome predicts cancer treatment response similarly to mutant allele fraction	19
Abstract C030: Functional characterization of VS-186B, a novel HDAC inhibitor for cancer treatment	19
Abstract A054: Evaluation of HER3-targeting ADC patritumab deruxtecan in irinotecan-resistant colorectal cancer PDX models reveals resistance mechanisms and informs rational combination strategies	19
Abstract C121: Single-cell RNA profiling reveals metastatic capacity of the malignant cells underlying microvascular invasion in patients with hepatocellular carcinoma	18
Abstract A053: Targeting Acquired Resistance to KRASG12D Inhibitors: designing rationale synergistic treatments	18
Abstract B032: Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)	18

Abstract C135: CBL0137 as a promising therapeutic strategy for anaplastic, treatment-emergent neuroendocrine prostate cancer	18
Abstract B064: TRI-611, a selective, CNS-penetrant molecular glue degrader of ALK with anti-tumor activity against preclinical models of ALK-fusion positive non-small cell lung cancer including kinase	18
Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy	17
Expression of Concern: ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance	17
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity	17
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer	17
Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma	17
The Role of Siglec-15 in Tumor Immunity: Mechanisms and Therapy	17
IL15/IL15Rα Complex Induces an Antitumor Immune Response following Radiotherapy only in the Absence of Tregs and Fails to Expand Progenitor TCF1+ CD8 T Cells	17
Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells	17
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0	17
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors	17
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab	17
ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin	17
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET -Amplified EGFR TKI–Resistant Lung Cancer	17
Abstract A012: Comparative analysis of circulating variant allele fractions in healthy individuals and patients with solid tumors using an ultra-sensitive liquid biopsy assay MUTE-Seq	16
Abstract C127: Modulating the tumor niche-specific protein corona of nanomedicines for the precision targeting of chemoresistant cells using patient-derived organoids	16
Abstract B061: In vivo benchmarking of trastuzumab deruxtecan (T-DXd) activity in panel of 400 XPDX models	16
Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts	16
Selected Articles from This Issue	16
Abstract A073: Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF -mutated primary and brain met	16
Abstract C055: Incidence of gastrointestinal adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled trials	16
Abstract C088: Intelligent Hit Discovery Platform for Accelerated Cyclic Peptide Radiopharmaceutical Development	16
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer	16
Selected Articles from This Issue	16
Abstract B090: Radiation-induced oral mucositis to rapidly determine effective radiosensitizing dosing regimens for ATM and DNAPK inhibitors	16
Abstract B142: EO3001: A novel agent for ARID1A mutant cancers	16
Abstract B082: Assessment of prevalence and utilization of tumor mutational burden and microsatellite instability in cancer patients at a community cancer center	16
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.	16
STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition	15
Translating Preclinical Studies into the Clinic: Assays and Endpoints Selected to Determine Efficacy	15
Reducing Dietary Protein Enhances the Antitumor Effects of Chemotherapy through Immune-Mediated Mechanisms	15
Cross-resistance of Belinostat and Romidepsin in Non–T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP	15
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on	15
Abstract B036: A novel PDE10 inhibitor that blocks RAS and β-catenin signaling and enhances tumor immunogenicity with robust activity to inhibit tumor growth and metastasis	15
Targeting DDR2 for Treating Pancreatic Cancer	15
Abstract C048: Chemoproteomic-enabled fragment-based drug discovery target identification in small cell lung cancer	15
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer	15
In Vivo Analysis of Neuroblastoma Targeting Potential of aGD2–SIRPα Fusion Antibodies for Local CD47 Blockade	15
IMiDs Augment CD3-Bispecific Antibody–Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production	15
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors	15
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors	15
All- trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin	15
TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy	15
Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors	14
Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas	14
Abstract B084: Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials	14
Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers	14
Selected Articles from This Issue	14
Abstract C059: Development of a Differentiated, Best-in-Class Oral Cbl-b Inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy	14
Abstract A036: Synthetic RNA-guided combinatorial targeting of glioblastoma adaptive resistance: Dual suppression of PI3K-AKT and mesenchymal transition escape pathways	14
Combination of Bremachlorin PDT and Immune Checkpoint Inhibitor Anti–PD-1 Shows Response in Murine Immunological T-cell–High and T-cell–Low PDAC Models	14
Selected Articles from This Issue	14
Abstract A078: Molecule Glue Profiling Unveils the Dynamics of KRAS-Induced Proximity	14
Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells	14
Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors	13
Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors	13
Abstract B126: The effects of Amaryllidaceae plant constituents narciclasine, lycorine and haemanthamine on chronic lymphocytic leukemia cells	13
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource	13
Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma	13
Abstract B009: Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and	13
Abstract C062: MED12 loss promotes PD-L1–mediated immune evasion and predicts response to immune checkpoint inhibitors in NSCLC	13
Decreased DNA Damage and Improved p53 Specificity of RITA Analogs	13
NOC2L Promotes Paclitaxel Resistance in Various Types of Ovarian Cancers by Decreasing NDUFA4 through Histone Acetylation Suppression	13
Current Status and Challenges of Vaccination Therapy for Glioblastoma	13
Abstract A088: Revealing intrinsic ATPase activity in kinases: Implications for drug discovery using ADP-Glo assay	13
Abstract C106: Validated novel Immuno-therapeutic targets for lung cancer revealed by SpliceIOTM- Innovative platform that identifies disease-specific alternative splicing	13
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia	13
MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells	13
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer	12
Target-Specific Locked Nucleic Acid Gapmer Decreases Growth and Metastases of Pancreatic Cancer	12
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios	12
Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme	12
Augmenting Chemokine CCL21 Enhances the Effectiveness of CTLA4 Blockade Immunotherapy for Head and Neck Squamous Carcinoma	12
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems	12
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity	12
Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas	12
Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads	12
Selected Articles from This Issue	12
Abstract C063: Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience	12

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition	12
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies	12
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma	12
MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma	12
Abstract A102: Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy Trial	12
Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study	11
Abstract A126: CDR609: A First-in-Class LGR5-targeted T Cell Engager for treatment of Colorectal Cancer and other solid tumors	11
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis	11
Abstract C046: Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study	11
CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues	11
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerabili	11
Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect	11
Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes	11
Abstract A001: Prevalence of Common HLA Class I Alleles in a Spanish Oncology Cohort Prescreened for Early-Phase Trials: Implications for Broadening Access to HLA-Restricted Therapies	11
TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma	11
FOXN Transcription Factors: Regulation and Significant Role in Cancer	11
Abstract B034: A chemoproteomic-enabled phenotypic library screen identifies KIF23 as a novel target in Ewing sarcoma	11
Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer	11
ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors	11
Targeting Transcriptional Cyclin-Dependent Kinases in Cancer	11
Abstract C004: ADC screening platform, a useful platform for ADC drug evaluation	11
Abstract A123: Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients	11
Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy	11
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy	11
Identification of CD74-positive antigen presenting glioma cells in primary human tumors and murine models of NF1 high-grade glioma	11
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency	10
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model	10
Predicting the Abscopal Phenomenon—Letter to the Editor	10
Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specific T Cell Cytotoxicity	10
Abstract A049: Impact of Actionable Genomic Alterations (AGA) on the Efficacy of Durvalumab in Patients with Locally Advanced NSCLC Treated with Concurrent Chemoradiotherapy	10
Abstract A019: Single-cell analysis of tumor population diversity in synovial sarcoma	10
Selected Articles from This Issue	10
Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy	10
Abstract B094: Modelling ADC sensitivity and mode-of-action in human cancer derived organoids	10
Abstract C006: Fitness landscape modeling indicates decreased effectiveness of microtubule assembly targeting drugs in tumors demonstrating chromosomal instability (CIN)	10
Abstract A097: Global pharmacodynamic effects uncovered with AP3 phosphoproteomic profiling of novel WEE1/PKMYT1 inhibitor ACR-2316 reveals the critical importance of PLK1 for ACR-2316’s superior prec	10
Abstract A116: Characterization of micvotabart pelidotin target binding properties and extracellular payload release	10
Abstract C120: TACC3 is a driver of metastasis in centrosome-amplified breast cancer	10
Abstract A040: Resistance to trastuzumab deruxtecan acquired through multifaceted pathway alterations in preclinical models	10
First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter	10
Abstract C124: MCAT™: A 3D Co-Culture Platform for Genome-Wide CRISPR Screening to Identify Stromal-Driven Vulnerabilities in CMS4 Colorectal Cancer	10
Abstract C118: A Non-Canonical role of cGMP Links PDE5A Inhibition to Metastasis Suppression	10
Abstract A121: Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics	10
Abstract B087: A translational platform of patient-derived xenografts (PDXs) for upper gastrointestinal cancers	10
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance	9
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells	9
Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells	9
Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites	9
Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer	9
TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer	9
Selected Articles from This Issue	9
N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase	9
Selected Articles from This Issue	9
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer	9
ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance	9
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy	9
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy	9
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models	9
Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies	9
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects	9
A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer	9
Retraction: FOXO3a Mediates the Cytotoxic Effects of Cisplatin in Colon Cancer Cells	9
Radiation Synergizes with IL2/IL15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity	9
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate	9
A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies	9
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors	9
Modular Smart Molecules for PSMA-Targeted Chemotherapy	9
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel	9
Abstract C051: Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omics data and organoid studies	8
Abstract A118: Discovery of HMPL-A251, a first-in-class HER2-directed antibody-targeted therapy conjugate (ATTC) with a novel PI3K/PIKK inhibitor payload	8
FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma	8
Abstract A037: Coordinated activity between AR-V7 and glucocorticoid receptor drives resistance to androgen receptor signaling inhibition	8
Abstract C094: Tumor-associated fibroblasts drive taurine accumulation and radiotherapy resistance in renal cell caecinoma via the CXCL12/CXCR4/SLC6A6 axis	8
Abstract A007: Is liquid biopsy a reliable surrogate for MSI testing? A concordance study using matched tissue and ctDNA-based NGS	8
Abstract A058: Investigating metformin as a unique therapeutic for KRAS-mutant non-small cell lung cancer	8
Abstract A061: Identification and validation of integrin β1 as an in vivo -specific combination partner with MAPK pathway inhibitors in BRAF mutant color	8
IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion	8
Abstract B046: Dimerization of SLFN12 by the PDE3A-SLFN12 complex is required for velcrin-induced toxicity in cancer cells	8
Abstract A114: Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study	8
Abstract C053: Acrivon Therapeutics’ generative ensemble model (KaiSR) accurately predicts and expands proprietary, actionable kinase-substrate relationships globally for the human kinome	8
Abstract C100: Therapeutic targeting of microRNA-31 promotes chemosensitivity via ATOX1 in pancreatic ductal adenocarcinoma	8
A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes	8
Antineoplastic Activity of a Novel Trispecific Single-Chain Antibody Targeting the hERG1/β1 Integrin Complex and TRAIL Receptors	8
Abstract B043: Activation Lethality through the WNT/beta-catenin pathway drives efficacy in colorectal cancer	8
Abstract A144: Clinical and morphological characteristics as a predictors of the development of radioiodine resistance in thyroid cancer	7
Abstract A110: Proteasome inhibitor (PI) ADC: A novel broad spectrum payload platform	7
Abstract A090: Vepugratinib (LY3866288), a potent highly isoform-selective FGFR3 inhibitor, enhances the activity of enfortumab vedotin (EV) in FGFR3-altered metastatic urothelial cancer (mUC) models	7
Abstract C013: Discovery of novel functional allosteric pockets on p53 using the AMPSTM screening platform	7
Abstract A115: Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy	7
Abstract A050: Effectiveness of PROTAC BET degraders ARV-825 and ARV-771 in combating chemoresistance in HNSCC	7
Abstract A047: Bis-indole derived dual NR4A1/2 inverse agonists synergistically enhance temozolomide-induced cytotoxicity in glioblastoma cells through downregulation of drug-resistance genes	7
Abstract C067: Screen failures in early-phase oncology trials: A single-center UK analysis of decentralized recruitment methods	7
Abstract C103: Inhibition of MGAT1 overcomes STK11-driven immune evasion in non-small cell lung cancer	7
Abstract B130: DUP9, a novel ecteinascidin derivative, as a payload for antibody drug conjugates, exhibits promising preclinical efficacy	7
Abstract B054: Correspondence between circulating tumor DNA (ctDNA)-based ERBB2 amplification and HER2 expression by IHC/ISH across solid tumors: Molecul	7